Brain Mechanisms of COVID-19-Sleep Disorders

Semyachkina-Glushkovskaya, O.; Mamedova, Aysel; Vinnik, Valeria; Klimova, Maria; Saranceva, Elena; Ageev, Vasily; Yu, Tingting; Zhu, Dan; Penzel, Thomas; Kurths, Jürgen

doi:10.3390/ijms22136917

Cited by 33 publications

(31 citation statements)

References 185 publications

(283 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, almost 72% of participants also reported feeling lonely, nervous, or anxious during these times. It is also important to highlight that 22.1% of the participants reported having started taking medication prescribed by the doctor to control the increase in anxiety, difficulty falling asleep or depression due to COVID-19, also known as coronasomnia [58]. Out of 5 people, 4 were concerned about being infected with COVID-19.…”

Section: Discussionmentioning

confidence: 99%

Pharmacological Adherence Behavior Changes during COVID-19 Outbreak in a Portugal Patient Cohort

Midão

Almada

Carrilho

et al. 2022

IJERPH

View full text Add to dashboard Cite

Concerns, behaviours, and beliefs influence how people deal with COVID-19. Understanding the factors influencing adherence behaviour is of utmost importance to develop tailored interventions to increase adherence within this context. Hence, we aimed to understand how COVID-19 affected adherence behaviour in Portugal. A cross-sectional online survey was conducted between 1 March and 3 April 2021. Descriptive statistics were performed, as well as univariable and multivariable regression models. Of the 1202 participants, 476 who were taking at least one medication prescribed by the doctor were selected. Of these, 78.2% were female, and the mean age was 40.3 ± 17.9 years old. About 74.2% were classified as being highly adherent. During the pandemic, 8.2% of participants reported that their adherence improved, while 5.9% had worsened adherence results. Compared with being single, widowers were 3 times more prone to be less adherent (OR:3.390 [1.106–10.390], p = 0.033). Comorbid patients were 1.8 times (OR:1.824 [1.155–2.881], p = 0.010) more prone to be less adherent. Participants who reported that COVID-19 negatively impacted their adherence were 5.6 times more prone to be less adherent, compared with those who reported no changes (OR:5.576 [2.420–12.847], p < 0.001). None of the other variables showed to be significantly associated with pharmacological adherence.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacological Adherence Behavior Changes during COVID-19 Outbreak in a Portugal Patient Cohort

Midão

Almada

Carrilho

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Sleep deficiencies have been observed with increased frequency during the pandemic in HCW (health care workers), the general population and patients with COVID. Collectively, sleep deficiencies observed in the context of the pandemic have been termed ‘coronasomnia’ in the media and by some authors [ 59 , 60 , 61 ].…”

Section: Epidemiology Of Sleep Deprivation During the Pandemicmentioning

confidence: 99%

Time to Sleep?—A Review of the Impact of the COVID-19 Pandemic on Sleep and Mental Health

Neculicioiu

Colosi

Costache

et al. 2022

IJERPH

View full text Add to dashboard Cite

Sleep is intrinsically tied to mental and overall health. Short sleep duration accompanies the modern lifestyle, possibly reaching epidemic proportions. The pandemic and subsequent lockdowns determined a fundamental shift in the modern lifestyle and had profound effects on sleep and mental health. This paper aims to provide an overview of the relationship between sleep, mental health and COVID-19. Contrasting outcomes on sleep health have been highlighted by most reports during the pandemic in the general population. Consequently, while longer sleep durations have been reported, this change was accompanied by decreases in sleep quality and altered sleep timing. Furthermore, an increased impact of sleep deficiencies and mental health burden was generally reported in health care workers as compared with the adult general population. Although not among the most frequent symptoms during the acute or persistent phase, an increased prevalence of sleep deficiencies has been reported in patients with acute and long COVID. The importance of sleep in immune regulation is well known. Consequently, sleep deficiencies may influence multiple aspects of COVID-19, such as the risk, severity, and prognosis of the infection and even vaccine response.

show abstract

“…Нарушения сна широко распространены среди лиц, перенесших COVID-19. Их распространенность достигает 34-40% [69][70][71][72][73][74][75][76][77][78], что соответствует полученным нами результатам: у 2/3 пациентов, обратившихся в клинику по поводу тревоги, отмечались расстройства сна. Это связывают с нарушением проницаемости гематоэнцефалического барьера и негативным влиянием провоспалительных цитокинов, в частности синтазы оксида азота [69].…”

Section: Discussionunclassified

“…Их распространенность достигает 34-40% [69][70][71][72][73][74][75][76][77][78], что соответствует полученным нами результатам: у 2/3 пациентов, обратившихся в клинику по поводу тревоги, отмечались расстройства сна. Это связывают с нарушением проницаемости гематоэнцефалического барьера и негативным влиянием провоспалительных цитокинов, в частности синтазы оксида азота [69]. Таким образом, положительное влияние Грандаксина ® на качество и структуру сна может быть объяснено положительным влиянием на нитроксидергическую систему ЦНС.…”

Section: Discussionunclassified

“…Проникновение провоспалительных цитокинов в ЦНС, их производство активированной микроглией при COVID-19 приводят к снижению уровня гаммааминомасляной кислоты в головном мозге у больных, дисбалансу между уровнем гамма-аминомасляной кислоты и глутамата у перенесших COVID-19. Более того, исследование, проведенное с использованием транскраниальной магнитной стимуляции, подтвердило снижение ГАМК-ергической активности у пациентов с постковидным синдромом [49,[65][66][67][68][69][70].…”

Section: Neuropsychiatric Disordersunclassified

See 1 more Smart Citation

Dynamics of vegetative, insomnia and neuropsychological manifestations during the treatment of post-COVID syndrome

et al. 2022

View full text Add to dashboard Cite

Introduction. Asthenia, vegetative manifestations, sleep disturbances and psycho-emotional background are companions of the coronavirus infection, the issue of drug correction of which is especially relevant. These symptoms disrupt the habitual way of life of patients for a long time, and in special cases lead to disability.Aim. To study the mental, somatoform and cognitive aspects of anxiety disorders after coronavirus infection during treatment with tofisopam (Grandaxin®) 150 mg/day.Materials and methods. The study included patients who had experienced a new coronavirus infection, who, after the end of treatment for the underlying disease, had complaints suggesting the presence of an anxiety disorder. The Hamilton scale was used to assess the level of anxiety. Examination of patients was carried out before the start of treatment, after 2, 4 and 6 weeks of therapy.Results and discussion. Prior to the start of therapy, all patients had an overall high level of anxiety: the average HAM-A score was 31.4 ± 2.92 points. At the end of Grandaxin® therapy, all patients showed a decrease in the level of anxiety: the average HAM-A score was 12.08 ± 2.27 points (p < 0.001). The maximum decrease in the severity of vegetative disorders was noted by the end of the 6th week of therapy with Grandaxin®. Thus, the indicator of this subscale decreased by more than 2 times – from 2.46 ± 0.54 to 1.05 ± 0.28 points (p < 0.001). The severity of insomnia during six weeks of therapy with Grandaxin® decreased from 2.56 ± 0.54 to 0.96 ± 0.45 points (p < 0.001).Conclusion. Psycho-emotional disorders (more often in the form of increased personal anxiety), sleep disorders, vegetative disorders, asthenic syndrome significantly affect the quality of life of patients who have had a new coronavirus infection. Involvement of the structures of the autonomic nervous system and central structures that regulate GABAergic transmission leads to significant vegetative failures, which requires pathogenetically substantiated drug correction of these disorders.

show abstract

Brain Mechanisms of COVID-19-Sleep Disorders

Cited by 33 publications

References 185 publications

Pharmacological Adherence Behavior Changes during COVID-19 Outbreak in a Portugal Patient Cohort

Pharmacological Adherence Behavior Changes during COVID-19 Outbreak in a Portugal Patient Cohort

Time to Sleep?—A Review of the Impact of the COVID-19 Pandemic on Sleep and Mental Health

Dynamics of vegetative, insomnia and neuropsychological manifestations during the treatment of post-COVID syndrome

Contact Info

Product

Resources

About